Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

ABSTRACT:

Purpose

Contemporary tumor-directed therapies for metastatic castration-resistant prostate cancer (mCRPC) are approved to prolong life, but their effects on symptoms such as pain are less well understood as a result of the lack of analytically valid assessments of pain prevalence and severity, clinically meaningful definitions of therapeutic benefit, and methodologic standards of trial conduct. This study establishes pain characteristics in the mCRPC population using a PRO measure.

Materials and methods

Patients with prostate cancer participated in an anonymous survey at five US comprehensive cancer centers in the Prostate Cancer Clinical Trials Consortium that incorporated the Brief Pain Inventory (BPI), analgesic use, and interference with daily activities. Prevalence and

SUBMITTER: Autio KA 

PROVIDER: S-EPMC3994234 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature